Navigation Links
ViroPharma to Release 2009 Second Quarter Financial Results on July 29, 2009
Date:7/14/2009

EXTON, Pa., July 14 /PRNewswire-FirstCall/ -- ViroPharma Incorporated's (Nasdaq: VPHM) second quarter financial results for 2009 are expected to be released on Wednesday, July 29, 2009 before the open of the U.S. financial markets.

The company will host a conference call and live audio webcast at 9:00 a.m. Eastern Time on the same day. During the conference call, ViroPharma management will discuss the 2009 second quarter and other business.

The press release and the live webcast of the conference call will be accessible via ViroPharma's corporate website athttp://www.viropharma.com. An audio archive will be available at the same address until August 21, 2009. To participate in the conference call, please dial (888) 299-4099 (domestic) and (302) 709-8337 (international). After placing the call, please tell the operator you wish to join the ViroPharma investor conference call.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. ViroPharma commercializes Cinryze(TM) (C1 esterase inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ViroPharma to Present at the Maxim Group First Annual Growth Conference
2. ViroPharma to Present at the UBS Global Life Sciences Conference
3. ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results
4. ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM)
5. ViroPharma to Present at the 26th Annual JP Morgan Healthcare Conference
6. ViroPharma Augments Senior Management
7. ViroPharma Provides Update on Vancocin(R)
8. Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma
9. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results
10. ViroPharma Incorporated Reports First Quarter 2008 Financial Results
11. ViroPharma to Release 2008 Second Quarter Financial Results on July 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... Prominant bariatric surgeon ... is thrilled to offer the recently FDA-approved Obalon Balloon System to his patients. ... SkyLex Advanced Surgical’s already comprehensive list of weight-loss services. Dr. Liu is ...
(Date:3/28/2017)... NJ (PRWEB) , ... March 28, 2017 , ... ... Camp Association’s Tri-State Camp Conference in Atlantic City March 13-16, was a busy ... their team of professional staff discussed strategies for preventing outbreaks among camp communities ...
(Date:3/28/2017)... ... ... Silicon Valley Hair Institute, the San Francisco Bay Area leader in women's ... loss. Although hair transplant procedures can be seen as more of a man’s issue, ... two reasons a woman may see her hair thinning. , “We are used to ...
(Date:3/28/2017)... ... March 28, 2017 , ... Thank you to all who attended Capio Partners ... This event was exclusive to providers and offered an opportunity to collaborate and network ... the Manchester Grand Hyatt where attendees gathered for a lively discussion on trends and ...
(Date:3/28/2017)... ... ... a thrilling adventure that reveals the mystery of Kevin’s purpose. “A Prophets Bones” is the ... had asked of him that he had neglected to do, but this was from God ... were some who would have felt themselves to be special and better than others due ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... -- ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company, announced ... efficacy studies. The company is harnessing the power of ... A, in an effort to find a better treatment ... 4 weeks of treatment in transgenic mice, the lead ... a full toxicology report of various organs. Cytotoxic T-cells ...
(Date:3/27/2017)... March 27, 2017 Medtec ... and more than 600 exhibitors from 70 countries ... and solutions that will advance the medical technology ... at the Messe Stuttgart, Stuttgart, Germany ... technology platform showcasing the key trends and insights ...
(Date:3/27/2017)... , March 27, 2017  A new ... (AADE) found that Medicare,s Competitive Bidding Program (CBP) significantly ... testing supplies. The lack of choice forces beneficiaries to ... have dire health consequences. AADE,s survey ... by AADE and others pointing out the inherent problems ...
Breaking Medicine Technology: